• Profile
Close

'Vaccine won't kill you': AIIMS Director allays fears

IANS Jan 19, 2021

AIIMS Director Randeep Guleria on 18 January allayed apprehensions about the coronavirus vaccines and assured that the side-effects will not result in death of the beneficiary.

For our comprehensive coverage and latest updates on COVID-19 click here.


The nationwide COVID vaccination drive had commenced on January 16 and a total of 447 adverse events following immunisation (AEFI) were reported during the first two days, with most of them being minor along with three cases of hospitalisation. "Even if a person takes Crocin or Paracetamol, they may develop allergic reactions. There is nothing to worry about. There is no side-effect which would result in death," Dr Guleria said. He added, "Main side-effects are body ache, fever, pain at injection site which subside in 1-2 days and take place in less than 10 percent of people. If the side-effects are severe, there could be skin rashes, nausea, difficulty in breathing."

The AIIMS Director said that people must come forth to get vaccinated if they want India to come out of the COVID-19 pandemic, decrease the mortality rate, bring the economy back on track and reopen schools. On January 16, moments after the Prime Minister launched the vaccination drive across the country, the jab was administered to the AIIMS chief on live telecast. Dr Guleria was the third person to take the shot in the institute. "I have no side-effects. I am feeling perfectly alright," he told the media, two days after taking the jab, in a bid to allay fears and apprehensions about the safety of the coronavirus vaccines.

The rollout of Oxford's 'Covishield' vaccine, manufactured by Serum Institute of India, and Bharat Biotech's 'Covaxin' began in the country amid apprehensions about the safety of the latter. Covaxin is currently undergoing late-stage clinical trials which are crucial to determining the efficacy of the shot. 'Covaxin' has been in the spotlight ever since it received the green signal from the drug regulator for restricted emergency use. The approval without adequate efficacy data drew flak from public health advocacy groups, researchers, scientists and activists. Meanwhile, as many as 2,24,311 beneficiaries have received doses of COVID-19 vaccines in the last two days. Only 17,072 beneficiaries were vaccinated in six states on Day 2.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay